Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies



Rating:

Share or cite this content

Citations should be made in the following way:
K. Rabe (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, MI, United States of America), M. Jenkins (Cambridge, United Kingdom), M. Patel (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America). Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial. 791

Member's Comments

No comment yet.

Related content which might interest you: Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017 Year: 2018 Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results Source: International Congress 2016 – Endoscopic lung volume reduction I Year: 2016 Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Effects of case management on hospitalisation and exacerbation rate in severe, complex COPD: A randomized controlled trial Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care Year: 2011 Interval exercise for patients with severe COPD – randomised trial [SRCTN11611768] Source: Annual Congress 2006 - Organisation and programmes in pulmonary rehabilitation Year: 2006 Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT) Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2 crossover patient outcomes. Source: Virtual Congress 2020 – The hot and cold of interventional pulmonology Year: 2020 Comprehensive care programme for patients with chronic obstructive pulmonary disease (COPD) --- A randomized controlled trial (RCT) Source: International Congress 2015 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2015 Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012